Natac Natural Ingredients SA · BME:NAT
Natac Natural Ingredients SA — Investor Presentation (January 2025)
27 slides from Natac Natural Ingredients SA's investor presentation, January 2025
Slide 1: January 2025
January 2025
Slide 2: Who are we?
Who are we? We are an established business group in the natural ingredients market, specialized in the research, development, Our differentiation lies in our ability to develop innovative manufacturing and marketing of plant extracts and Omega-3 products tailored to the specific oils for the nutrace
Slide 3: Evolution
Evolution 2024 2018 2016 Launching of the As 2012 2014 2020 2022 Somozas factory, and start of the production and marketing of Olive extracts Opening of Launching of Natac, ranked among the Construction of a Omega-3 oil production commercial products with 65 most innovative SMEs new multi-product Op
Slide 4: International presence
International presence The strategic location of our production, R&D and Quality units EUROPE USA in Spain ensures the highest 8.95% SPAIN 8.38% 69.41% quality standards and compliance with European regulations ASIA ASIA 11.93% 23,38% 92% Exports 0.09% LATAM 1.24% Percentages based on ordinary reven
Slide 5: What do we do?
What do we do? Provision of NUTRACEUTICAL PHARMACEUTICAL FEED FOOD OMEGA3 SERVICES 42% 42% 11% 1% 1% 3% We work closely with We supply active Our portfolio includes a We assist our clients in At our Omega-3 plant in We provide research and companies in this sector pharmaceutical wide range of the de
Slide 6: Mission Vision Values
Mission Vision Values Transferring scientific knowledge Being a global benchmark company in We are a committed, customer- to sustainable and industrially viable improving the quality of life by focused team driven by the pursuit projects generating value and applying the benefits of nature through o
Slide 7: ESG - Environmental, Social and Governance
E S G - Environmental, Social and Governance RELIABLE PARTNER THERE IS NO PLANET B PERSONS We aim to be a trusted partner for our customers, Our clear and firm objective is to reduce our At Natac we are firmly committed to our team and producing ingredients while ensuring supply, quality, environmen
Slide 8: Market
Market 9EUROPE ,3% 67,23% The natural extracts and Omega-3 NATURAL EXTRACTS OMEGA-3 and sectors are in full expansion with significant growth in recent years Revenue 2030 CAGR 2020-2030 Revenue 2030 CAGR 2020-2030 118,6B% 118,6B% 118,6B% • There is currently a shift in customer 97.57B Revenue 9% Rev
Slide 9: Market
Market World Market Trend Plant Extracts vs NATAC World Market Trend Omega-3 vs NATAC 300 100,00 90,00 250 80,00 200 70,00 60,00 150 50,00 40,00 100 30,00 50 20,00 10,00 0 0,00 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Cervicom Technavio
Slide 10: Value Chain
Value Chain R&D capacity Sustainability and Production Quality control Efficiency Vertical procurement of capacity business model raw materials Natac's team of Natac has developed experts conducts a highly efficient Natac operates the most The company has thorough research to business model both It
Slide 11: Business Model
Business Model A sustainable business model ensuring the optimal utilization Resources of resources, transforming them into value-added ingredients with a positive impact on people’s health Bioenergy and bio-fertilisers Agri-food industry Benefits of the model: Leader in natural ingredients enhancin
Slide 12: Board of Directors, Executive and Steering Committee
BOARD OF DIRECTORS EXECUTIVE AND STEERING COMMITTEE Aldabi Inversiones, S.L.U., represented by Mr. Antonio Ángel Delgado Romero, Mr. Antonio Delgado Romero, Chief Executive Officer and Co-Founder (*) Chairman Mr. José Carlos Quintela Fernández, Vicepresident and Co-Founder Idoasis 2002, S.L., repres
Slide 13: Analyst coverage
Analyst coverage Analysts' reports on the company are available on Natac's website, under the Investors section Analyst: Analyst: Analyst: César Sánchez Grande David Lopez. Luis Esteban Arribas Most recent target price: Most recent target price: 0.84/share 0.80/share View Report View Report View Rep
Slide 14: Why invest in Natac?
Why invest in Natac? High atomization Consolidation in the Sectors with Spectacular Entry in Continuous ESG and entry barriers pharmaceutical strong growth evolution Omega-3 innovation Commitment sector annual The group operates in Natac, a leader in the The plant extracts An agreement has The group
Slide 15: Evolution of the business model 2024 vs 2023
Evolution of the business model in 24 vs 23 % Distribution of net revenue by business % Distribution of net revenue by segments 2024 geographical region 2024 GEOGRAPHICAL REGION 2024 2023 %VAR Sale Product SPAIN 2,908,281.52 2,123,988.18 36.93% EUROPE (*) 24,096,284.78 12,233,573.91 96.97% ASIA 4,14
Slide 16: Business development by sector and market of plant extracts
Business development by sector and market of plant extracts Revenues by sector Revenues by market 16.000.000,00 30.000.000,00 14.000.000,00 25.000.000,00 12.000.000,00 10.000.000,00 20.000.000,00 8.000.000,00 15.000.000,00 6.000.000,00 10.000.000,00 4.000.000,00 5.000.000,00 2.000.000,00 0,00 0,00 2
Slide 17: Evolution of revenues and normalized EBITDA
Evolution of revenues and normalized EBITDA Net sales and EBITDA EBITDA and % EBITDA growth 35,851.01 35.000,00 13,816.18 16 500% 30.000,00 13,82 450% 26,554.98 14 442.74% 400% 25.000,00 22,408.97 12 350% 20,359.00 9,411.76 10 9,41 20.000,00 300% 17,583.11 8,02 269.72% 8,021.33 8 7,62 250% 7,621.42
Slide 18: Evolution Sales/Employees
Evolution Sales/Employees Evolution sales/Number of employees 40.000.000 35.000.000 225 30.000.000 25.000.000 171 175 152 20.000.000 133 125 15.000.000 90 10.000.000 84 75 63 5.000.000 36 0 25 2018 2019 2020 2021 2022 2023 2024 Net sales No. Employees 18
Slide 19: Evolution of sales of vegetable extracts
Evolution of sales of vegetable extracts Growth trend of Natac sales growth vs vegetable extracts sector 500% 400% 300% 200% 100% 0% 2018 2019 2020 2021 2022 2023 2024 NATAC SALES GROWTH INDUSTRY AVERAGE 19
Slide 20: Forecast fulfillment evolution
Forecast fulfillment evolution COMMENTS In 2024, the group achieved a net turnover of €35.85 million, which MAIN FINANCIAL KPIS represents 86% fulfillment of the revenue target. The variance is primarily 2024E 2024R DEGREE OF COMPLIANCE (Amounts in millions of Euros) explained by the delay in Omega-
Slide 21: DFN/EBITDA 2024
DFN/EBITDA -2024 Without Composition of financial debt Consolidated 2024 Consolidated convertible loans without grants and grants Consolidated without Consolidated without convertible loans Total debt 80,119,935.98 67,624,799.45 57,322.786.49 grants or grants €67.62M €57.32M Tota cash 568,983.09 568
Slide 22: Financial Highlights
Financial Highlights Total revenues Normalized EBITDA 40,00 2021 2022 2023 2024 35.85 16,00 35,00 13.82 Total revenues 20,359 22,409 26,555 35,851 14,00 30,00 26.55 Normalized EBITDA 8,021 7,621 9,412 13,816 12,00 Normalized EBITDA margin 39.40% 34.01% 35.44% 38.54% 25,00 22.41 9.41 20.36 10,00 8.02
Slide 23: 2025-2026 Plan
2025-2026 Plan ESTIMATED 2025 2026 Total income >€55 M >€68 M 60,00 Normalized EBITDA >€20 M >€26 M 50,00 13.62 40,00 ANNUAL GROWTH 2023 - 2024 30,00 9.41 Total income 35.01 % 7.62 8.02 7.25 Normalized EBITDA 46.80 % 20,00 35.85 4.33 26.55 10,00 20.36 22.41 2.55 17.58 14.07 YEAR-ON-YEAR GROWTH 2020
Slide 24: Business Plan
Business Plan 1 2 3 4 5 Launch of the Omega- Agreement with U.S. Entry into the APIS Expansion of the Hervás Revenue growth from 3 plant pharmaceutical company: production market factory - Sustainext new markets increased operations volume Completion and operational A U.S. pharmaceutical company Ent
Slide 25: Headquarters
Headquarters EUROPE PRODUCTION CENTERS AMERICA APAC Headquarters Commercial Office Commercial Office Av. Rita Levi Montalcini, 14 Ctra. Córdoba-Málaga Km.98, 14915 3 Shenton Way, #08-04 2825 E Cottonwood 28906 - Getafe El Tejar, Cordoba, Spain Pkwy Suite 500 Shenton House Madrid, Spain Salt Lake Cit
Slide 26: Glossary of terms
Glossary of terms ▪ TOTAL AMOUNT OF TURNOVER ▪ DFN Revenues - product sales: revenues generated from the commercialization of natural plant Acronym for Net Financial Debt, which indicates the level of financial debt of Natac extracts and Omega-3. Natural Ingredients Group on a consolidated basis. Th
Slide 27: Thank you!
Thank you!
Natac Natural Ingredients — Investor Presentation (January 2025) on 6ix